Wells Fargo & Company downgraded shares of Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) from an overweight rating to an equal weight rating in a report issued on Thursday, MarketBeat.com reports ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) gapped up prior to trading on Friday after Scotiabank raised their price target on the stock from $430.00 to $433.00. The stock had ...

The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or injuries.

A new type of painkiller aimed at treating pain from an injury or surgery has been approved by the US Food and Drug Administration (FDA). The drug suzetrigine, also known by its brand name Journavx, ...

Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...

A new drug approved Thursday by the FDA offers pain management but is not addictive. Unlike opioids, it treats pain signals ...

It's the first new pharmaceutical approach to treating pain in over 20 years, designed to eliminate risks of addiction and ...

The Food and Drug Administration announced Thursday its approval of suzetrigine, the first new painkiller greenlit by the ...

The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

The FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with opioids.

Lee — With a proposal by Vertex Towers LLC for a special permit to construct a 150-foot cell tower on Beaver Dam Road, the ...